Clinical study of Bevacizumab combined with Paclitaxel Liposome and Tegafur Gimeracil and Oteracil Potassium in the treatment of medium and advanced gastric cancer
XU Zhen ZUO Yun LU Weidong
Oncology Department, Zhangjiagang First People′s Hospital, Jiangsu Province, Zhangjiagang 215600, China
Abstract：Objective To study the clinical effect of Bevacizumab combined with Paclitaxel Liposome and Tegafur Gimeracil and Oteracil Potassium in the treatment of medium and advanced gastric cancer. Methods Ninety patients with medium and advanced gastric cancer who were treated in the Oncology Department of Zhangjiagang First People′s Hospital from April 2012 to December 2017 were selected and divided into study group and control group according to different treatment methods, with 45 cases in each group. The control group was treated with Paclitaxel Liposome combined with Tegafur Gimeracil and Oteracil Potassium, while the study group was treated with Bevacizumab on the basis of the control group. The clinical efficacy, serum carbohydrate antigen 724 (CA724), carbohydrate antigen 199 (CA199) levels, adverse reactions, quality of life and immune function were compared between the two groups. Results The total effective rate of the study group (88.89%) was higher than that of the control group (68.89%), and the difference was statistically significant (P ＜ 0.05). The levels of CA724 and CA199 in the two groups after treatment were significantly lower than before treatment, and the differences were all highly statistically significant (all P ＜ 0.01). The levels of serum CA724 and CA199 in the study group were all significantly lower than those in the control group, and the differences were all highly statistically significant (all P ＜ 0.01). There were no significant differences in the incidence of leukopenia, nausea and vomiting, abnormal renal and liver function and alopecia between the two groups (all P ＞ 0.05). The Karnofsky performance score of the study group was significantly higher than that of the control group after treatment, and the difference was highly statistically significant (P ＜ 0.01). The levels of CD4+ and CD4+/CD8+ in the study group were significantly higher than those in the control group, and the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). Conclusion Bevacizumab combined with Paclitaxel Liposome and Tegafur Gimeracil and Oteracil Potassium is effective in the treatment of medium and advanced gastric cancer. It is worth popularizing and applying.
许震 左云 卢玮冬. 贝伐珠单抗联合紫杉醇脂质体+替吉奥治疗中晚期胃癌的临床研究[J]. 中国医药导报, 2019, 16(23): 106-109,117.
XU Zhen ZUO Yun LU Weidong. Clinical study of Bevacizumab combined with Paclitaxel Liposome and Tegafur Gimeracil and Oteracil Potassium in the treatment of medium and advanced gastric cancer. 中国医药导报, 2019, 16(23): 106-109,117.
2019, Vol. 16 
京公网安备 11010502046598号